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Anti-Apoptotic NF-jB and ‘‘Gain of Function’’ mutp53
in Concert Act Pro-Apoptotic in Response to
UVBþ IL-1 via Enhanced TNF Production
Ines Mu¨ller1,2, Stefan Beissert1 and Dagmar Kulms1,2
In response to genotoxic stress, including UVB radiation, transcription factors NF-kB and p53 inevitably influence
the cellular fate. Loss of p53 function has been attributed to malignant transformation and interferes with
therapeutic interventions, whereas ‘‘gain of function’’ mutants even enhance tumor promotion. Constitutive
NF-kB activation is linked to tumor maintenance and resistance against chemotherapy. The cross talk between
p53 and NF-kB, however, is still under debate. Using the non-transformed keratinocyte cell line HaCaT, we shed
light on the interplay between p53 and NF-kB by providing clear evidence that chronically activated NF-kB
together with designated ‘‘gain of function’’ mutp53 promotes apoptosis via cooperative tumor necrosis factor
(TNF) production in response to UVBþ IL-1. Performing chromatin immunoprecipitation analysis we demonstrate
that both transcription factors bind to the TNF promoter, whereas UVB-induced inhibition of Ser-Thr-
phosphatase protein phosphatase 2A facilitates prolonged phosphorylation of NF-kB and the transcriptional
cofactor cAMP response element–binding protein, both being required for extended TNF transcription. Thus,
two major anti-apoptotic factors, NF-kB andmutp53, in concert may generate pro-apoptotic responses. As human
skin is constantly exposed to UVB, causing IL-1 production as well, we hypothesize that the remarkable amount
of hotspot p53 mutations within the epidermis (4%) may serve a protective function to eliminate precancerous
cells at an early stage.
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INTRODUCTION
In response to cellular stresses, the cross talk between pro- and
anti-apoptotic factors determines the cellular fate. Whereas
activation of the tumor-suppressor p53 causes upregulation of
pro-apoptotic genes following genotoxic stress (Seitz et al.,
2010), activation of the transcription factor nuclear factor kB
(NF-kB) is mainly associated with anti-apoptotic responses
(Fujioka et al., 2012; Almeida et al., 2014). Inactivation of p53
is observed in most human cancers, with mutations in p53
occurring in about 50% of all tumors (Soussi and Wiman,
2007), reaching up to 90% in non-melanoma skin cancer
(Gervin et al., 2003). Intriguingly, in addition to ‘‘loss of
function’’ mutants that lack the tumor-suppressive function,
‘‘gain of function’’ mutp53 variants lose the sequence-specific
DNA binding but exert complex DNA interactions instead,
thereby modifying the set of target genes expressed (Goehler
et al., 2005; Kim and Deppert, 2007). Accordingly, contact
(p53R248W) and structural (p53R175H) mutations are
enabled in order to promote a large spectrum of cancer
phenotypes and contribute to drug resistance (Moll et al.,
2005; Deppert, 2007; Vousden and Lane, 2007). In contrast to
wtp53, both mutants were shown to confer a selective advan-
tage during tumor development, although the individual
mechanisms are still under debate (Mello and Attardi, 2013).
NF-kB is mainly triggered in response to pro-inflammatory
cytokines, including IL-1. Receptor-driven activation of a
downstream kinase cascade involving IkB-kinase b (IKKb)
causes proteasomal degradation of the inhibitor of kBa (IkBa),
allowing for nuclear translocation of NF-kB. Because consti-
tutive activation of NF-kB has been linked to transformation,
proliferation, and anti-apoptosis (Aggarwal, 2004), limitation
of its activity is warranted by negative feedback regulation
involving NF-kB-dependent transcription of IkBa (Delhase
et al., 1999). More recently, increasing evidence has been
found that additionally attribute pro-apoptotic functions to
NF-kB when exposed to DNA-damaging agents (Delhase et al.,
1999; Campbell et al., 2004; Liu et al., 2006; Szoltysek et al.,
2008; O’Prey et al., 2010; Narayanan et al., 2014). Accord-
ingly, previous work from our lab showed co-stimulation with
IL-1 to enhance UVB-induced apoptosis in epithelial cells by
accelerated NF-kB-dependent transcription of tumor necrosis
factor (TNF). Released TNF triggered TNF-R1 in an autocrine
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manner to additively promote apoptosis (Poppelmann et al.,
2005; Strozyk et al., 2006; Barisic et al., 2008; Witt et al., 2009;
Barisic et al., 2010).
A versatile cross talk between p53 and NF-kB seems to exist
especially in tumor cells, whereas in most cases mutual
inhibition has been proposed (Webster and Perkins, 1999;
Tergaonkar et al., 2002; Bohuslav et al., 2004; Tergaonkar,
2009). Also the competition of both transcription factors for
identical cofactors like CREB (cAMP response element–
binding protein) was shown to limit the relative activation
status of p53 versus NF-kB (Webster and Perkins, 1999;
Ikeda et al., 2000; Huang et al., 2007; Zschiedrich et al.,
2008; Tergaonkar, 2009; Spooren et al., 2010). In contrast,
other reports attribute a cooperative role to wtp53 and
NF-kB in apoptosis induction through mutual activation
(Ryan et al., 2000), collaborative promoter binding
(Ma et al., 2008), or direct protein–protein interaction
(Schneider et al., 2010). Less, however, is known about the
interplay between ‘‘gain of function’’ mutp53 and NF-kB in
response to genotoxic stress.
Utilizing the non-transformed keratinocyte cell line HaCaT
stably knocked down for p53 and/or stably inhibiting
NF-kB activation, we demonstrate that mutp53R248W and
mutp53R175H but not wtp53 cooperate with NF-kB through
direct binding to the TNF promoter. Consequently, acceler-
ated TNF production enhances apoptosis in response to
UVBþ IL-1. We further provide evidence that UVB-induced
inhibition of Ser-Thr-phosphatase protein phosphatase 2A
(PP2A) plays a crucial role in sustaining phosphorylation of
NF-kB-p65 and CREB to maintain both factors in an active
state over time. Hence, we report that two initially anti-
apoptotic factors, which are commonly present in various
cancers, in concert may promote pro-apoptotic responses.
RESULTS
Co-stimulation with IL-1 enhances UVB-induced apoptosis in an
NF-jB-dependent manner
In accordance with previous findings (Poppelmann et al., 2005;
Strozyk et al., 2006; Barisic et al., 2008), co-stimulation of
HaCaT keratinocytes with IL-1 significantly enhanced UVB-
induced apoptosis (Figure 1a). As this enhancement could be
blocked with an antagonistic TNF-R1 antibody, TNF-dependent
TNF-R1 activation seemed to affirm the underlying mechanism
as reported before (Poppelmann et al., 2005; Barisic et al.,
2008). Thus, enhancement of apoptosis was also evident by
pronounced processing of caspase-3 and poly(ADP-ribose)-
polymerase (PARP) (Figure 1b) and coincided with
considerable TNF release (Figure 1c). Similar to epithelial
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Figure 1. IL-1 enhances UVB-induced apoptosis due to pronounced tumor necrosis factor (TNF) release. (a) Cells were stimulated with IL-1, TNF, UVB, or a
combination of IL-1þUVB or TNFþUVB, or pretreated for 30 minutes with an antagonistic anti-TNF-R1 antibody. Apoptosis was determined with Cell Death
Detection ELISA. (b) Cleavage of caspase-3 and poly(ADP-ribose)-polymerase (PARP) was documented by Western-blotting. (c) TNF secretion was analyzed with
TNF ELISA. (d) Cells were stimulated with IL-1 or UVBþ IL-1 as indicated. Cytosolic and nuclear fractions were analyzed for IkBa depletion (cyt) by Western-
blotting and NF-kB activation (nuc) by electrophoretic mobility shift assay. (e) Cells were stimulated as in d and TNF expression determined by reverse
transcriptase–PCR. (f) IkBa status of HaCaT-IkBa super-repressor (IkBa-SR) cells was documented by Western-blotting. (g) HaCaT-mock and -IkBa-SR cells were
treated as in a, apoptosis was determined with Cell Death Detection ELISA, and (h) TNF release was documented with TNF ELISA. *Po0.05; **Po0.001. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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cells, TNF production in keratinocytes could be attributed to
disruption of the negative feedback regulation of NF-kB:
IL-1 stimulation caused transient NF-kB activation with
maximum degradation of IkBa after 30 minutes (Figure 1d).
Rapid NF-kB-dependent resynthesis entailed replenishment of
IkBa after 1–2 hours, which terminated nuclear NF-kB activity.
In contrast, co-stimulation with UVBþ IL-1 completely abro-
gated the reappearance of IkBa up to 6 hours, coinciding with
elevated nuclear NF-kB level (Figure 1d). Consequently,
prolonged transcription of TNF was facilitated upon UVBþ
IL-1 treatment (Figure 1e), being a prerequisite for enhanced
TNF secretion (Barisic et al., 2008). The notion that inhibition
of negative feedback regulation drives NF-kB-dependent TNF
production was confirmed in HaCaT cells stably overexpress-
ing an IkBa super-repressor (IkBa-SR; Figure 1f). Overall,
apoptosis was slightly enhanced, but more importantly, the
enhancing effect of IL-1 on UVB-induced apoptosis was
abrogated (Figure 1g) because of significantly reduced TNF
secretion (Figure 1h). Still, some residual TNF production
remained, indicating that additional factors might contribute
to elevated TNF production.
The intensity of DNA damage correlates with the apoptosis rate
induced and the amount of TNF released
Irradiation of cells with increasing doses of UVB caused gradual
enhancement of apoptosis (Figure 2a), which correlated with
increasing amounts of cyclobutane-pyrimidine dimer forma-
tion (Figure 2c). At a constant IL-1 level also the amount of
TNF secretion gradually increased (Figure 2b), implying a link
between DNA damage and TNF production. Conclusively, we
assumed an additional transcription factor to become acti-
vated in response to UVB-driven DNA damage that may
cooperate with NF-kB for full TNF production in response to
UVBþ IL-1.
p53 contributes to TNF-mediated enhancement of UVB-induced
apoptosis
The transcription factor p53 plays a crucial role in mediating
DNA damage responses. HaCaT cells are known to harbor
mutated p53, carrying heterozygous C-T transitions (Lehman
et al., 1993), changing it into a ‘‘gain of function’’-like pheno-
type. As ‘‘gain of function’’ mutations of p53 are known to
exert an anti-apoptotic phenotype, stable knockdown of p53
sensitized three different HaCaT-p53i clones to UVB-induced
apoptosis (Figure 3a and b), whereas the IL-1-mediated
upregulation (n-fold) appeared to be impaired in HaCaT-
p53i cells and also yielded less TNF (Figure 3d). The protein
level of other p53 family members, p63 and p73, remained
unaffected by loss of p53 (Figure 3c), indicating that solely
p53 might contribute to accelerated apoptosis and TNF
production in response to UVBþ IL-1. Accordingly, additional
inhibition of NF-kB by stably overexpressing IkBa-SR in
HaCaT-p53i cells (Figure 3e) minimized both, apoptosis
enhancement (Figure 3f) and TNF release (Figure 3g). Con-
clusively, data implied that both transcription factors may
collectively amplify the pro-apoptotic effect in UVBþ IL-1-
treated cells.
NF-jB and p53 additively promote TNF transcription in response
to UVBþ IL-1
Activation of the NF-kB subunit p65 is facilitated by Ser536
phosphorylation, whereas Ser15 phosphorylation is required
for p53 activation (Graham and Gibson, 2005; Ray et al.,
2012). Treatment of HaCaT cells with IL-1 caused transient
phosphorylation of p65, being terminated after 2 hours, the
time point of IkBa resynthesis. Phosphorylation of the trans-
criptional coactivator CREB at Ser133 (Friedrich et al., 2010)
followed the identical pattern, indicating that both proteins are
required for proper IL-1-induced transcription. The DNA
damage–responsive transcription factor p53 remained inactive
following IL-1 stimulation, as anticipated. In response to UVB,
instead, p65 stayed inactive, whereas phosphorylation of p53
rapidly occurred and lasted for at least 4 hours. Activation of
p53 also coincided with CREB phosphorylation, confirming
CREB to be an important cofactor for both transcription factors
(Huang et al., 2007). Finally, co-stimulation with UVBþ IL-1
allowed phosphorylation of all three components. Whereas
the phosphorylation pattern of p53 and CREB remained
unchanged compared with UVB-treated cells, p65 phos-
phorylation was extended (Figure 4a; (Barisic et al., 2008)).
Interestingly, knockdown of p53 did not influence the phos-
phorylation pattern of p65 and CREB (Figure 4b), implying that
NF-kB and p53 act additively but independently to enhance
TNF transcription. In accordance with this assumption,
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Figure 2. IL-1-induced enhancement of UVB-induced apoptosis and tumor
necrosis factor (TNF) release correlates with increased DNA damage. HaCaT
cells were stimulated with increasing doses of UVB (50–400 J m2) alone or
in combination with constant IL-1 doses (10 ng ml1). (a) After 16 hours,
apoptosis was determined in a Cell Death Detection ELISA and (b) TNF release
was documented in a TNF ELISA. (c) In parallel, genomic DNA was extracted
and UVB-induced DNA damage visualized by Southwestern dot-blot analysis
using an antibody directed against cyclobutane-pyrimidine dimers (CPD). Anti-
adenosine documented equal loading of genomic DNA.
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co-immunoprecipitation revealed that p65 and p53 do not
directly interact at the protein level (Figure 4c and d).
From previous studies, we knew that UVB-mediated inhibi-
tion of catalytic subunit of PP2A (PP2Ac) crucially contributes
to abrogation of negative feedback regulation for NF-kB
through chronic IKKb activation (Barisic et al., 2008, 2010).
We here discover an additional role for PP2A in tuning NF-kB
activity. In control cells, only treatment with UVBþ IL-1 caused
p65 phosphorylation, whereas p53 and CREB were activated by
UVB and UVBþ IL-1, respectively. Inhibition of PP2Ac by small
interfering RNA-mediated knockdown and addition of calyculin
A had no effect on p53 phosphorylation but significantly
stabilized phosphorylation of p65 and CREB (Figure 4e). These
results disclose two ways of PP2A-mediated NF-kB regulation:
indirectly by dephosphorylating IKKb to terminate nuclear
localization of NF-kB and directly by dephosphorylating p65
and CREB to terminate transcription (Figure 4f). Activation of
p53, instead, is exclusively driven in a DNA damage–responsive
manner and remains unaffected by PP2A.
Only mutp53 but not wtp53 binds to the TNF promoter to
enhance NF-jB-driven TNF transcription
According to our findings so far, we assumed that p65 and p53
may cooperatively bind to the TNF promoter in response to
UVBþ IL-1. This idea was strengthened by the finding that,
besides p65 and CREB consensus elements, a putative (partial)
p53 binding motive also exists within the TNF promoter
sequence ((Kuo and Leiden, 1999), Supplementary Figure S1
online). As expected, chromatin immunoprecipitation analysis
of p65 consolidated the prolonged association of NF-kB with
the TNF promoter in response to UVBþ IL-1 in semiquantita-
tive (Figure 5a) and quantitative PCR analyses (Figure 5b). In
order to dissect the binding properties of different p53 variants,
we overexpressed wtp53 as well as mutp53R248W and
mutp53R175H in HaCaT-p53i cells (Figure 5c). As assumed,
endogenous mutp53 bound to the TNF promoter for at least
2 hours following UVBþ IL-1 treatment (Figure 5d semiquan-
titative and 5e quantitative). Interestingly, wtp53 was shown to
hardly associate with the TNF promoter compared to
mutp53R248W and mutp53R175H (Figure 5d and e). Taken
together, binding of NF-kB and only ‘‘gain of function’’
mutp53 was significantly intensified over time, whereas
binding of wtp53 was neglectable. Concordantly, we could
identify different effects of wtp53 versus mutp53 expression on
apoptosis as well as TNF release (Figure 5f and g). IL-1-
mediated enhancement of UVB-induced apoptosis was stron-
ger in cells harboring mutp53— i.e. normal HaCaT cells as
well as mutp53R248W and mutp53R175H expressing HaCaT-
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p53i cells, and remained only marginal in HaCaT-p53i- and -
wtp53-expressing cells (Figure 5f). Of note, the apoptotic
responses correlated well with the amount of TNF released
by the individual cell lines. Data confirmed accelerated TNF
release to closely correlate with pronounced enhancement of
apoptosis and strengthens the view that this effect is most
pronounced in mutp53-expressing cells (Figure 5g).
Mutp53 prevents clonogenic outgrowth of UVBþ IL-1-treated
cells
Three weeks following UVB or UVBþ IL-1 stimulation,
clonogenic outgrowth of HaCaT-mock compared with
HaCaT-p53i cells was determined. Whereas cell density of
UVBþ IL-1-treated HaCaT-p53i cells reached an average 89%
compared with UVB-treated cells, only 77% cell density was
achieved for HaCaT-mock cells (Figure 6a and b). This
supported the concept that cell survival might be impaired
following UVBþ IL-1 treatment if p53 is mutated.
Taken together, we here disclose the cooperation of ‘‘gain
of function’’ mutp53 and NF-kB at the TNF promoter and
provide evidence that two initially anti-apoptotic proteins in
concert may generate pro-apoptotic responses.
DISCUSSION
Dysregulation of both p53 and NF-kB confers a selective
advantage during tumor development and conveys therapy
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resistance. A versatile cross talk between NF-kB and p53
exists at multiple levels; however, the balance between
synergistic and antagonistic processes may rely on the cellular
context. In the present study, we confirm the molecular
mechanism by which chronic NF-kB activation contributes
to enhancement of UVB-induced apoptosis via upregulation of
TNF in keratinocytes (Poppelmann et al., 2005; Barisic et al.,
2008).
Intriguingly, at a constant IL-1 concentration required for
NF-kB activation, increasing UVB exposure linked TNF
release to the intensity of DNA damage induced, pointing at
p53 to support TNF transcription. Hence, TNF release and
thereby IL-1-mediated enhancement of UVB-induced apopto-
sis was minimized in HaCaT-p53i-IkBa-SR cells.
Previous studies have described mutp53 to augment TNF-
induced NF-kB activity (Weisz et al., 2007) or have shown
that NF-kB-p65 is required for TNF-induced upregulation of
p53 target genes in different mouse tissues (Wang et al., 2009;
O’Prey et al., 2010). However, a collaboration of the two
transcription factors at the human TNF promoter has never
been reported. Even though NF-kB-p53 protein–protein inter-
actions have been proposed at responsive promoter elements
(Gurzov et al., 2010) or at NF-kB-responsive reporter
constructs (Kawauchi et al., 2008), we could not co-
immunoprecipitate p53 and p65 in UVBþ IL-1-exposed
cells. This indicates that both factors independently but
additively trigger the TNF promoter. The activation kinetics
for p65, p53, and the joint coactivator CREB clearly showed
UVB to activate p53 and also to extend IL-1-induced
activation for p65 and CREB. Although p53 phosphorylation
follows an established ataxia telangiectasia mutated-
dependent (ATM) mechanism (Zhang et al., 2011), we here
deciphered a PP2A-dependent mechanism that drives
prolonged p65 and CREB phosphorylation. On the basis of
current and former data, we propose the following scenario to
underlie activation of p53 and hyperactivation of NF-kB at the
TNF promoter.
IL-1 causes canonical activation of NF-kB, whereas UVB
activates p53. In parallel, UVB-induced inhibition of PP2Ac
allows for nuclear persistence of NF-kB (Barisic et al., 2008;
Witt et al., 2009; Barisic et al., 2010; Zhang et al., 2011;
Konrath et al., 2014) and warrants prolonged activation of p65
and CREB. The fact that NF-kB activity still vanishes at later
times point can be attributed to other IkB members, such as
IkBe, that take over NF-kB inhibition in a delayed and more
linear manner (Hoffmann et al., 2002).
Thus, the present study is of high patho-/physiological
relevance, because IL-1 is constantly produced from UVB-
exposed keratinocytes within human skin (Feldmeyer et al.,
2007). UVB radiation may serve as a carcinogen by activation
of skin oncogenes, inactivation of tumor suppressors, and
repression of cell-based immune responses that are generally
able to eliminate highly antigenic skin tumors (Yarosh and
Kripke, 1996). At the same time, UVB-induced DNA damage
is a prerequisite for execution of apoptosis, leading to elimina-
tion of cancer-prone cells (Kulms and Schwarz, 2000; Murphy
et al., 2001). The molecular switch, however, has not yet been
identified. As p53 carries hotspots for UVB-induced mutations,
numerous studies exist postulating 4% of all keratinocytes to
bare p53 mutations; however, less squamous cell carcinoma
develop (Murphy et al., 2001; Klein et al., 2010). It is further
common knowledge that up to 50% of all tumors and up to
90% of non-melanoma skin cancers bear p53 mutations
(Murphy et al., 2001; Gervin et al., 2003), clearly supporting
that mutp53 selectively promotes tumor progression once the
oncogenic pressure exceeds a certain threshold. Still, we
hypothesize that at sub-oncogenic stresses and concomitant
IL-1 production, provided e.g. by keratinocytes from the
microenvironment, expression of mutp53 may even be
beneficial for mildly damaged cancer-prone cells to enforce
their elimination via TNF-dependent apoptosis.
In addition, the present study sheds light on the ongoing
discussions about the p53–NF-kB interplay in cancer and may
have even broader implications regarding cancer treatment,
where currently a lot of effort is made to reconstitute wtp53
and/or inhibit NF-kB in cancer cells (Lin and Karin, 2003;
Muller and Vousden, 2013).
MATERIALS AND METHODS
Results of quantitative PCR, Cell Death Detection-, and TNF-ELISA
are presented as mean±SD of three independently performed
experiments. Reverse transcriptase–PCR, electrophoretic mobility shift
assay, and western blot analyses represent one out of three indepen-
dently performed experiments. For statistical analysis, Student’s t-test
was performed.
Cells and reagents
The human keratinocyte cell line HaCaT (Fusenig et al., 1990) was
cultured in DMEM, 10% fetal calf serum, and 1% PenStrep (Thermo
Scientific, Waltham, MA) and irradiated with UVB (300 J m 2)
using TL12 fluorescent bulbs (290–320 nm, Philips; Eindthoven,
the Netherlands) or stimulated with recombinant human IL-1b
(10 ng ml 1) or TNF (100 ng ml 1; both R&D Systems, Minneapolis,
MN). TNF-R1 was blocked with an antagonistic antibody H-398
(40mg ml 1) kindly provided by Dr Peter Scheurich, University of
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Figure 6. Mutp53 prevents clonogenic outgrowth of UVBþ IL-1-treated cells.
(a) Percentage of clonogenic outgrowth of HaCaT-mock versus -p53i cells 3
weeks after UVB and UVBþ IL-1 stimulation, respectively. Outgrowth of UVB-
only treated cells is set as 100% and the cell density of UVBþ IL-1-treated cells
calculated accordingly. **Po0.01. (b) Display of one representative experiment.
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Stuttgart, Germany. TNF release was measured in a TNF ELISA (R&D
Systems) and apoptosis in a Cell Death Detection-ELISA (Roche,
Mannheim, Germany). For PP2Ac knockdown, 1.6 105 cells were
transfected with 120 pmol scrambled 50-gCggCUgCCggAAUUU
ACCTT-30 or PP2Ac 50-gAggUUCgAUgUCCAgUUATT-30 small
interfering RNA (MWG, Ebersberg, Germany) using Lipofectamin
2000 (Thermo Scientific). Calyculin A (Cell Signaling, Beverley, MA)
was added at 5mM. Transfectants were generated by electroporating
6.5 106 cells in DMEM, 10% fetal calf serum, and 1.5% DMSO
with 25mg of plasmids encoding pRetroSuper-blasto-p53 (Zalcenstein
et al., 2003), IkBa-S32/36A (pBKCMV-IkB-SR), or mock (pcDNA3;
EasyjecT-plus, Peqlab, Erlangen, Germany) and stable clones selected
with blasticidine (5mg ml 1) or G418 (1,7 mg ml 1, PAA, Co¨lbe,
Germany). Silent mutations were introduced into pCMV-neo-Bam-
based expression constructs (p53wt, p53R175H, p53R248W) using a
Quick Change Site-directed Mutagenesis Kit (Stratagene, Kirkland,
WA) and the following primers: F: 50-ATCACACTggAAgATAg
CTCCggCAACCTTCTAggACggAACAgC-30; R: 50-gCTgTTCCgTCCTAg
AAggTTgCCggAgCTATCTTCCAgTgTgAT-30.
Electromobility shift analysis
Cells were lysed in low-salt buffer (10 mM HEPES, pH 7.9; 10 mM KCl;
0.1 mM EDTA; 0.1 mM EGTA; 1 mM dithiotreitol; 0.1 mM phenyl-
methylsulfonylfluoride, Complete; Roche) on ice for 20 minutes.
Nuclear pellets were lysed in high-salt buffer (20 mM HEPES, pH
7.9; 400 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM dithiotreitol;
0.1 mM phenylmethylsulfonylfluoride, Complete; Roche). The NF-kB
consensus oligo-nucleotide (sc-2505; Santa Cruz, Heidelberg, Ger-
many) was end-labeled using [g32P] ATP and T4 polynucleotide
kinase (Thermo Scientific), and purified using a QIAquick Nucleotide
Removal Kit (Qiagen, Minden, Germany). Binding reactions compris-
ing 15mg protein extract, 4ml of 5 binding buffer (20 mM HEPES,
pH 7.5; 50 mM KCl; 2.5 mM MgCl2; 20% (w/v) ficoll; 1 mM dithio-
treitol), 2mg poly[dIdC], 2mg BSA, and 70,000 c.p.m. 32P-labeled NF-
kB consensus nucleotide were incubated for 20 minutes at room
temperature, separated on 4% native PAGE, and detected autoradio-
graphically (Strozyk et al., 2006).
Immunoprecipitation and western blot analysis
Cells were lysed in lysis buffer (50 mM HEPES, pH 7.5; 150 mM NaCl;
10% glycerol; 1% Triton X-100; 1.5 mM MgCl2; 1 mM EGTA; 100 mM
NaF; 10 mM pyrophosphate; 0.01% NaN3, Complete, PhosSTOP,
Roche), subjected to 7.5–15% SDS-PAGE, blotted, and incubated
with antibodies (b-actin, #4970; caspase-3, #9665; CREB, #9197;
phospho-CREB, #9198; GAPDH, #2118; IkBa #4814; phospho-p53,
#9284; phospho-p65, #3033; PP2Ac, #2038—Cell Signaling; p53,
554293; poly(ADP-ribose)-polymerase, 551025—BD Biosciences,
Heidelberg, Germany; p63, sc-843; p65, sc-8008—Santa Cruz;
p73, PC385—Calbiochem, Darmstadt, Germany) and visualized by
chemiluminescent detection (SuperSignal, Thermo Scientific). For
immunoprecipitation, protein extracts were incubated with anti-p53
or -p65 antibody (#9282; #8242, Cell Signaling) and protein-A-
Agarose (KPL, Gaithersburg, ML) beads overnight at 4 1C. Proteins
were eluted and subjected to western blot analysis.
Southwestern dot-blot analysis
Genomic DNA was extracted according to the manufacturer’s protocol
(Qiagen). A volume of 2mg DNA in denaturation buffer (1.5 M NaCl;
0.5 M NaOH) was vacuum dot-blotted onto a nylonþ membrane,
neutralized (1 M Tris; 2 M NaCl), and fixed for 15 minutes at 80 1C.
Cyclobutane-pyrimidine dimers were detected with KTM53 antibody
(Kamiya Biomedical, Thousand Oaks, CA) and equal loading was
monitored with anti-adenosine (Research Plus Inc., Manasquan, NJ).
Semiquanititative reverse transcriptase–PCR
RNA was extracted using GIT buffer and reverse-transcribed with an
AMV Reverse Transcriptase kit (Thermo Scientific). Primers were used
in a 20-ml reaction utilizing the RedTaq polymerase system (Sigma,
St Louis, MO): GAPDH: F: 50-gCCTCCTgCACCACCAACTgC-30; R:
50-CCCTCCgACgCCTgCTTCAC-30; TNF: F: 50-TgCTTgTTCCTCAgCC
TCTT-30; R: 50ATCCCAAAgTAgACCTgCCC-30.
Chromatin Immunoprecipitation
Cells were crosslinked in 1% formaldehyde, 125mM Glycine added, and
lysed in lysis buffer (10mM Tris, pH 7.5; 10mM NaCl; 3mM MgCl2; 2.5%
NP40; 10mM MG-132; PhosSTOPs, Completes, Roche). Pelleted nuclei
were resuspended in chromatin immunoprecipitation-buffer (10mM Tris,
pH 8.0; 1mM EDTA pH 8.0; 0.5mM EGTA pH 8.0; 10mM MG-132;
PhosSTOPs and Completes, Roche), chromatin sheared (Covaris S2,
Woburn, MA) at 20dc 8i 200 cps fs 600s, diluted in buffer (16.7mM Tris,
pH 8.0; 1.2mM EDTA pH 8.0; 167mM NaCl; 1.1% Triton X-100; 0.01%
SDS; 10mM MG-132; PhosSTOPs, Completes, Roche), and precleared
by adding Sepharoses CL-4B (Sigma). Complexes were precipitated
with anti-p-p53 (#9284, Cell Signaling) or p65 (sc-372, Santa Cruz)
antibody and Protein-A-Sepharose 4 Fast Flow (Thermo Scientific)
overnight at 4 1C. Precipitates were washed in low-salt buffer (20mM
Tris, pH 8.1; 150mM NaCl; 2mM EDTA; 1% Triton X-100; 0.1% SDS),
high-salt buffer (20mM Tris, pH 8.1; 500mM NaCl; 2mM EDTA;
1% Triton X-100; 0.1% SDS), wash buffer (10mM Tris, pH 8.0; 1mM
EDTA; 1% deoxycholate; 1% NP40; 0.25M LiCl), and Tris-EDTA buffer
(10mM Tris, pH 8.0, 1mM EDTA). Complexes were eluted
(0.1M NaHCO3; 1% SDS) and crosslinking reversed in 0.2 M NaCl
overnight at 65 1C. After proteinase K treatment (55 1C, 3hours) and
phenol–chloroform extraction, DNA fragments were analyzed using the
DyNAmo ColorFlash SYBR Green qPCR kit in a PikoReal24 cycler with
PikoReal 2.2 software (Thermo Scientific): p65: F: 50-CCACAgCAA
TgggTAggAgAATg-30; R: 50-TTCATgAAgCTCTCACTTCTCAg-30; p53:
F: 50-CgggTCAgAATgAAAgAAgAAg-30; R: 50-gAgggAAAAgCTgTg
TTgAg-30.
Clonogenic assay
A total of 50,000 cells were seeded in a 10-cm dish, stimulated, and
medium changed every other day. After 3 weeks, cells were stained
with crystal violet and dissolved in KH2PO4–ethanol, and absorption
measured at 595 nm.
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